FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319293879> ?p ?o ?g. }

• W4319293879 endingPage "175883592211489" @default.
• W4319293879 startingPage "175883592211489" @default.
• W4319293879 abstract "Background: Although immune checkpoint inhibitors (ICIs) and targeted therapies have been widely used as adjuvant treatment for resected melanoma, the optimal therapy remains controversial. Therefore, we conducted this updated network meta-analysis (NMA) to assess the efficacy and tolerability of adjuvant therapies for cutaneous melanoma. Methods: PubMed, Embase, Cochrane library, and Web of Science were systematically searched for relevant literatures published in the last 30 years. Disease-free survival (DFS), overall survival (OS), and serious adverse events were considered as the efficacy and tolerability outcomes. Results: In all, 27 randomized controlled trials (RCTs) including 16,709 stage III–IV melanoma patients were enrolled in this NMA. For BRAF wild-type melanoma, our analysis showed that both nivolumab and pembrolizumab demonstrated significantly better DFS and tolerability than ipilimumab (10 mg/kg). Nivolumab, pembrolizumab, ipilimumab (3 mg/kg), and ipilimumab (10 mg/kg) all appeared to be effective in prolonging OS, but no therapy demonstrated significantly better OS than ipilimumab (10 mg/kg). Nivolumab + ipilimumab showed the best DFS, but did not appear to be effective in improving OS and ranked only seventh in tolerability. Vaccines and granulocyte-macrophage colony-stimulating factor therapies were well tolerated, but all failed to improve the DFS or OS in stage III melanoma patients. In terms of BRAF mutation-positive melanoma, ICIs (nivolumab + ipilimumab, nivolumab, pembrolizumab, ipilimumab; 10 mg/kg) exhibited comparable efficacy to dabrafenib + trametinib, and all these therapies showed significantly better DFS than placebo. Conclusion: Considering efficacy and tolerability, nivolumab and pembrolizumab seem to be preferable adjuvant therapies for patients with stage III–IV melanoma. For BRAF mutation-positive patients, more RCTs are still required to determine which is better between ICIs and targeted therapy." @default.
• W4319293879 created "2023-02-07" @default.
• W4319293879 creator A5032773676 @default.
• W4319293879 creator A5039815113 @default.
• W4319293879 creator A5047740393 @default.
• W4319293879 creator A5049331080 @default.
• W4319293879 creator A5074490801 @default.
• W4319293879 date "2023-01-01" @default.
• W4319293879 modified "2023-10-18" @default.
• W4319293879 title "Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis" @default.
• W4319293879 cites W1501513289 @default.
• W4319293879 cites W1585375233 @default.
• W4319293879 cites W1718139154 @default.
• W4319293879 cites W1903128087 @default.
• W4319293879 cites W1908752382 @default.
• W4319293879 cites W1968603371 @default.
• W4319293879 cites W1982967337 @default.
• W4319293879 cites W1989710243 @default.
• W4319293879 cites W2005224124 @default.
• W4319293879 cites W2006436962 @default.
• W4319293879 cites W2018221216 @default.
• W4319293879 cites W2021108393 @default.
• W4319293879 cites W2049553585 @default.
• W4319293879 cites W2070825440 @default.
• W4319293879 cites W2096870516 @default.
• W4319293879 cites W2098923148 @default.
• W4319293879 cites W2103017208 @default.
• W4319293879 cites W2104445971 @default.
• W4319293879 cites W2104885590 @default.
• W4319293879 cites W2105660133 @default.
• W4319293879 cites W2107429737 @default.
• W4319293879 cites W2111999709 @default.
• W4319293879 cites W2115111964 @default.
• W4319293879 cites W2115293121 @default.
• W4319293879 cites W2118449798 @default.
• W4319293879 cites W2120415677 @default.
• W4319293879 cites W2123659815 @default.
• W4319293879 cites W2124262559 @default.
• W4319293879 cites W2129814407 @default.
• W4319293879 cites W2130760938 @default.
• W4319293879 cites W2131772284 @default.
• W4319293879 cites W2137978694 @default.
• W4319293879 cites W2142970896 @default.
• W4319293879 cites W2143995805 @default.
• W4319293879 cites W2155798268 @default.
• W4319293879 cites W2164130643 @default.
• W4319293879 cites W2166630161 @default.
• W4319293879 cites W2168167318 @default.
• W4319293879 cites W2171746061 @default.
• W4319293879 cites W2175254188 @default.
• W4319293879 cites W2248320823 @default.
• W4319293879 cites W2269457085 @default.
• W4319293879 cites W2317565093 @default.
• W4319293879 cites W2339783374 @default.
• W4319293879 cites W2343271354 @default.
• W4319293879 cites W2411252792 @default.
• W4319293879 cites W2526607882 @default.
• W4319293879 cites W2560367415 @default.
• W4319293879 cites W2566484518 @default.
• W4319293879 cites W2585271320 @default.
• W4319293879 cites W2588681363 @default.
• W4319293879 cites W2590715063 @default.
• W4319293879 cites W2725988420 @default.
• W4319293879 cites W2752210999 @default.
• W4319293879 cites W2783914781 @default.
• W4319293879 cites W2788938550 @default.
• W4319293879 cites W2791512052 @default.
• W4319293879 cites W2797309423 @default.
• W4319293879 cites W2799475392 @default.
• W4319293879 cites W2886963239 @default.
• W4319293879 cites W2894584497 @default.
• W4319293879 cites W2894796660 @default.
• W4319293879 cites W2898179628 @default.
• W4319293879 cites W2916508569 @default.
• W4319293879 cites W2940595430 @default.
• W4319293879 cites W2964599082 @default.
• W4319293879 cites W2964751282 @default.
• W4319293879 cites W2964993184 @default.
• W4319293879 cites W2987115201 @default.
• W4319293879 cites W2990870977 @default.
• W4319293879 cites W2991341799 @default.
• W4319293879 cites W2996038327 @default.
• W4319293879 cites W2997351648 @default.
• W4319293879 cites W3004472410 @default.
• W4319293879 cites W3024460671 @default.
• W4319293879 cites W3081861280 @default.
• W4319293879 cites W3082456432 @default.
• W4319293879 cites W3083986479 @default.
• W4319293879 cites W3087697977 @default.
• W4319293879 cites W3088170039 @default.
• W4319293879 cites W3089316941 @default.
• W4319293879 cites W3093383535 @default.
• W4319293879 cites W3119100447 @default.
• W4319293879 cites W3124720941 @default.
• W4319293879 cites W3126577181 @default.
• W4319293879 cites W3131681136 @default.
• W4319293879 cites W3135677912 @default.
• W4319293879 cites W3153228158 @default.

• next